Lupin Ltd
NSE:LUPIN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lupin Ltd
NSE:LUPIN
|
IN |
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
CN |
|
C
|
Custodian REIT PLC
LSE:CREI
|
UK |
|
Rayonier Inc
NYSE:RYN
|
US |
|
Nacity Property Service Group Co Ltd
SSE:603506
|
CN |
Lupin Ltd
In the bustling landscape of the global pharmaceutical industry, Lupin Ltd. stands as a testament to the transformative power of innovation and strategic foresight. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin embarked on its journey with a clear vision: to deliver high-quality drugs at affordable prices. Over the years, it has adeptly navigated the complex world of pharmaceuticals to become a formidable player in the generics market. Its success is built on a robust portfolio that includes a diverse range of generic and branded formulations across many therapeutic segments such as cardiovascular, diabetology, asthma management, and anti-tuberculosis. The company prioritizes intensive research and development, paving the way for both the introduction of new generics and the development of advanced drug delivery systems. Such focus ensures Lupin maintains a competitive edge in both established markets like the United States and emerging markets across Asia and Africa.
The company’s financial engine is powered largely by its extensive manufacturing and distribution capabilities, which are strategically positioned across the globe to maximize efficiency and meet demand. With state-of-the-art facilities in India supplemented by strategic acquisitions and partnerships overseas, Lupin produces a wide array of active pharmaceutical ingredients (APIs) and finished dosages, allowing it to capture value across different stages of the drug supply chain. This vertically integrated model not only enhances profit margins but also provides the agility to respond quickly to market shifts. Furthermore, Lupin's strategic emphasis on biosimilars and specialty drugs reinforces its commitment to innovation, unlocking new revenue streams amid growing global healthcare demands. As Lupin continues to expand its footprint, it remains anchored in its mission to improve healthcare outcomes, embodying a legacy where profitability harmoniously aligns with purpose.
In the bustling landscape of the global pharmaceutical industry, Lupin Ltd. stands as a testament to the transformative power of innovation and strategic foresight. Founded in 1968 by Dr. Desh Bandhu Gupta, Lupin embarked on its journey with a clear vision: to deliver high-quality drugs at affordable prices. Over the years, it has adeptly navigated the complex world of pharmaceuticals to become a formidable player in the generics market. Its success is built on a robust portfolio that includes a diverse range of generic and branded formulations across many therapeutic segments such as cardiovascular, diabetology, asthma management, and anti-tuberculosis. The company prioritizes intensive research and development, paving the way for both the introduction of new generics and the development of advanced drug delivery systems. Such focus ensures Lupin maintains a competitive edge in both established markets like the United States and emerging markets across Asia and Africa.
The company’s financial engine is powered largely by its extensive manufacturing and distribution capabilities, which are strategically positioned across the globe to maximize efficiency and meet demand. With state-of-the-art facilities in India supplemented by strategic acquisitions and partnerships overseas, Lupin produces a wide array of active pharmaceutical ingredients (APIs) and finished dosages, allowing it to capture value across different stages of the drug supply chain. This vertically integrated model not only enhances profit margins but also provides the agility to respond quickly to market shifts. Furthermore, Lupin's strategic emphasis on biosimilars and specialty drugs reinforces its commitment to innovation, unlocking new revenue streams amid growing global healthcare demands. As Lupin continues to expand its footprint, it remains anchored in its mission to improve healthcare outcomes, embodying a legacy where profitability harmoniously aligns with purpose.
Record Revenue: Lupin reported another record quarter, with revenue surpassing the previous high and marking 14 consecutive quarters of year-on-year growth.
Broad-Based Growth: Growth was strong across the U.S., India, Europe, Latin America, and other emerging markets, with most regions delivering double-digit year-on-year increases.
U.S. Outperformance: The U.S. business achieved its highest-ever sales, driven by new product launches like Tolvaptan and Mirabegron, and supported by base business and seasonal tailwinds.
Margin Expansion: EBITDA margin rose to 31.1%, up 681 basis points year-on-year, with gross margins at 73.5%, a 420 basis point improvement driven by product mix and cost efficiencies.
Upgraded Guidance: Full-year EBITDA margin guidance was raised to 27–28% from 25–26%, reflecting the strong performance.
Pipeline Momentum: The company highlighted a strong pipeline, especially in injectables and biosimilars, with the FDA approval and pending launch of pegfilgrastim in the U.S.
India Prescription Strength: India’s core prescription business grew 10.9% year-on-year in Q3, well ahead of the market, with chronic therapies now 67% of the portfolio.
Strategic Investments: Lupin continues to invest heavily in R&D (7.5% of sales) and technology, including AI, and is expanding its specialty and complex product offerings through organic growth and acquisitions.
